How Should Synthetic Follow-Ons of Biological Products Be Regulated? What Are the Implications for Automatic Substitution?

Authors

  • Jens Heisterberg Novo Nordisk A/S, Søborg, Denmark

DOI:

https://doi.org/10.33892/aph.2021.91.108-109

Keywords:

Biological, synthetic, biosimilar, generic, automatic substitution

Published

2021-11-15

How to Cite

(1)
Heisterberg, J. How Should Synthetic Follow-Ons of Biological Products Be Regulated? What Are the Implications for Automatic Substitution?. Acta Pharm Hung 2021, 91, 108-109.

Issue

Vol. 91 No. 3-4 (2021): Abstracts of DDRS 2021 Conference, November 15-17, 2021, Budapest, Hungary

Section

Short communication

Copyright (c) 2021 Acta Pharmaceutica Hungarica

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

APH is published as a diamond open-access journal under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Creative Commons License